Using a real-world cohort of US veterans, researchers examine the effectiveness of durvalumab consolidation in unresectable stage III NSCLC. Read more
While evidence is mixed on the efficacy of some non-traditional methods, Dr. Deepti Behl says lung cancer physicians should be familiar with the options and support patients who are willing to try to stop smoking. Read more
Upcoming IASLC meetings offer educational opportunities around the globe. Read more for registration and abstract news from LACLC, ACLC, and TTLC. Read more
During IASLC’s North America Conference on Lung Cancer, MD Anderson’s Dr. Tina Cascone reviewed the evidence for neoadjuvant and adjuvant therapy in NSCLC. Read more
Dr. Solange Peters showed 24-month overall survival rates were higher with tremelimumab, durvalumab, and chemotherapy versus chemotherapy alone across all subgroups, including those with KRAS, STK11, and KEAP1 mutations. Read more
During WCLC 22, Dr. Renelle Myers demonstrated the importance of considering long-term cumulative exposure to air pollutants when assessing individual lung cancer risk. Read more
Long-term data presented by Dr. Charles Rudin during WCLC 2022 showed significant OS benefit for patients with extensive stage SCLC on pembrolizumab combination versus placebo. Read more
Former IASLC board member Dr. Carolyn Dresler recently honored for her lifetime of tobacco control advocacy. Penn Medicine chosen as site for US National Cancer Institute Telehealth Research Center of Excellence. Read more
During ESMO Congress 2022, Prof. Charles Swanton shared data that show cells with EGFR and KRAS gene mutations can turn cancerous when exposed to pollution from the burning of fossil fuels. Read more
In a Q&A with ILCN, Dr. Karen Kelly looks back at the moments that made lasting impressions and the presentations with the power to change the practice of thoracic oncology. Read more